Refractory Solid Tumor Clinical Trials

3 recruiting

Refractory Solid Tumor Trials at a Glance

14 actively recruiting trials for refractory solid tumor are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 1 with 9 trials, with the heaviest enrollment activity in Houston, Boston, and Portland. Lead sponsors running refractory solid tumor studies include TCRx Therapeutics Co.Ltd, Circle Pharma, and Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

Browse refractory solid tumor trials by phase

Treatments under study

About Refractory Solid Tumor Clinical Trials

Looking for clinical trials for Refractory Solid Tumor? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Refractory Solid Tumor trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Refractory Solid Tumor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

Solid TumorPediatric Solid TumorMalignant Solid Tumors+2 more
National Cancer Institute (NCI)10,000 enrolled3 locationsNCT03739827
Recruiting
Phase 1Phase 2

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

Refractory NeuroblastomaRefractory RhabdomyosarcomaRefractory Solid Tumors+3 more
Theodore Laetsch59 enrolled7 locationsNCT06721689
Recruiting
Phase 1

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)

Treatment-Refractory Solid Tumors
Bionoxx Inc.27 enrolled2 locationsNCT07190833
Recruiting
Phase 1Phase 2

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

Hepatocellular CarcinomaRefractory Solid TumorPediatric Solid Tumor+3 more
St. Jude Children's Research Hospital64 enrolled2 locationsNCT05468359
Recruiting
Phase 1

A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors

Refractory Solid Tumors
M.D. Anderson Cancer Center48 enrolled1 locationNCT06006273
Recruiting
Phase 1

Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

Lung CancerAdvanced Solid TumorMetastatic Solid Tumor+2 more
Circle Pharma220 enrolled10 locationsNCT06577987
Recruiting
Phase 1

Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression

Refractory Solid Tumor
The First Affiliated Hospital of Xiamen University20 enrolled1 locationNCT06375564
Recruiting
Phase 1Phase 2

Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

Advanced Refractory Solid TumorsAdvanced Triple Negative Breast CancersMetastatic Triple Negative Breast Cancers
National University Hospital, Singapore63 enrolled1 locationNCT05035745
Recruiting
Phase 1

NKG2D-CAR-NK92 Cells Immunotherapy for Solid Tumors

Relapsed/Refractory Solid Tumors
Henan Medical University20 enrolled1 locationNCT05528341
Recruiting
Early Phase 1

Personalized KSX01-TCRT in Patients With Advanced Solid Tumors

Refractory Solid TumorsRelapsed Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences12 enrolled1 locationNCT06150365
Recruiting
Phase 1

A Clinical Study of CHT101 in CD70-Positive Advanced Solid Tumors

Relapsed / Refractory Solid Tumor
Tianjin Medical University Cancer Institute and Hospital36 enrolled1 locationNCT06730659
Recruiting
Early Phase 1

Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors

Advanced Refractory Solid TumorsSubjects Considered Likely to Respond to CB-03-10
Cosmo Technologies Ltd90 enrolled6 locationsNCT03863145
Recruiting
Early Phase 1

KSX01-TCRT Injection Project in Solid Tumors

Refractory Solid TumorsRelapsed Solid TumorsTCR-T Cells
TCRx Therapeutics Co.Ltd50 enrolled1 locationNCT05811975
Recruiting
Early Phase 1

KSH01-TCRT Solid Tumors

Refractory Solid TumorsRelapsed Solid TumorsTCR-T Cells
TCRx Therapeutics Co.Ltd50 enrolled1 locationNCT05539833